HU204081B - Process for producing myeloperoxidase enzyme - Google Patents
Process for producing myeloperoxidase enzyme Download PDFInfo
- Publication number
- HU204081B HU204081B HU105188A HU105188A HU204081B HU 204081 B HU204081 B HU 204081B HU 105188 A HU105188 A HU 105188A HU 105188 A HU105188 A HU 105188A HU 204081 B HU204081 B HU 204081B
- Authority
- HU
- Hungary
- Prior art keywords
- enzyme
- myeloperoxidase
- purification
- blood cells
- white blood
- Prior art date
Links
- 102000003896 Myeloperoxidases Human genes 0.000 title claims abstract description 19
- 108090000235 Myeloperoxidases Proteins 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 25
- 108090000790 Enzymes Proteins 0.000 claims abstract description 25
- 238000000746 purification Methods 0.000 claims abstract description 10
- 239000002555 ionophore Substances 0.000 claims abstract description 5
- 230000000236 ionophoric effect Effects 0.000 claims abstract description 5
- 238000011210 chromatographic step Methods 0.000 claims abstract 2
- 210000000265 leukocyte Anatomy 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 10
- 235000019270 ammonium chloride Nutrition 0.000 claims description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 4
- 230000001885 phytohemagglutinin Effects 0.000 claims description 4
- 108090001090 Lectins Proteins 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 239000002523 lectin Substances 0.000 claims description 3
- 206010018910 Haemolysis Diseases 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 230000008588 hemolysis Effects 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 241000711408 Murine respirovirus Species 0.000 abstract description 8
- 230000004913 activation Effects 0.000 abstract description 5
- 102000014150 Interferons Human genes 0.000 abstract description 4
- 108010050904 Interferons Proteins 0.000 abstract description 4
- 102000015696 Interleukins Human genes 0.000 abstract description 4
- 108010063738 Interleukins Proteins 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000007858 starting material Substances 0.000 abstract description 4
- 108010062580 Concanavalin A Proteins 0.000 abstract description 3
- 239000012190 activator Substances 0.000 abstract description 3
- 229940079322 interferon Drugs 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 108010034897 lentil lectin Proteins 0.000 abstract description 2
- 239000005289 controlled pore glass Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- -1 phytohaemagglutinin Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000219739 Lens Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 229910000608 Fe(NO3)3.9H2O Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU105188A HU204081B (en) | 1988-03-04 | 1988-03-04 | Process for producing myeloperoxidase enzyme |
| JP5021189A JPH0663B2 (ja) | 1988-03-04 | 1989-03-03 | ミエロペルオキシダーゼの調整方法 |
| AT48089A AT391480B (de) | 1988-03-04 | 1989-03-03 | Verfahren zur herstellung des enzymes myeloperoxydase |
| DE19893907162 DE3907162A1 (de) | 1988-03-04 | 1989-03-06 | Verfahren zur herstellung des enzymes myeloperoxydase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU105188A HU204081B (en) | 1988-03-04 | 1988-03-04 | Process for producing myeloperoxidase enzyme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT50210A HUT50210A (en) | 1989-12-28 |
| HU204081B true HU204081B (en) | 1991-11-28 |
Family
ID=10952641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU105188A HU204081B (en) | 1988-03-04 | 1988-03-04 | Process for producing myeloperoxidase enzyme |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPH0663B2 (enrdf_load_stackoverflow) |
| AT (1) | AT391480B (enrdf_load_stackoverflow) |
| DE (1) | DE3907162A1 (enrdf_load_stackoverflow) |
| HU (1) | HU204081B (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2558492B1 (en) | 2010-04-14 | 2016-11-16 | F.Hoffmann-La Roche Ag | Immunoglobulin aggregate removal |
-
1988
- 1988-03-04 HU HU105188A patent/HU204081B/hu not_active IP Right Cessation
-
1989
- 1989-03-03 JP JP5021189A patent/JPH0663B2/ja not_active Expired - Lifetime
- 1989-03-03 AT AT48089A patent/AT391480B/de not_active IP Right Cessation
- 1989-03-06 DE DE19893907162 patent/DE3907162A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE3907162A1 (de) | 1989-09-14 |
| ATA48089A (de) | 1990-04-15 |
| JPH0663B2 (ja) | 1994-01-05 |
| JPH01269491A (ja) | 1989-10-26 |
| HUT50210A (en) | 1989-12-28 |
| DE3907162C2 (enrdf_load_stackoverflow) | 1992-05-21 |
| AT391480B (de) | 1990-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0317376B1 (fr) | Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques | |
| Palfree et al. | Yeast killer toxin: purification and characterisation of the protein toxin from Saccharomyces cerevisiae | |
| US3743722A (en) | Anti-coagulant isolation | |
| Lien et al. | Purification of a derepressible arylsulfatase from Chlamydomonas reinhardti: Properties of the enzyme in intact cells and in purified state | |
| JPH01238534A (ja) | エンドトキシンの除去方法 | |
| JPS59222421A (ja) | 抗トロンビン３・ヘパリン類濃縮物の製造法 | |
| Beydemir et al. | Purification and characterization of glucose 6-phosphate dehydrogenase from sheep erythrocytes and inhibitory effects of some antibiotics on enzyme activity | |
| HU204081B (en) | Process for producing myeloperoxidase enzyme | |
| CN109652398B (zh) | 凝血因子ⅹ激活剂rvv-ⅹ的制备方法及制得的rvv-ⅹ | |
| JPS61189228A (ja) | 血液凝固第８因子製剤の製法 | |
| US5814504A (en) | Protein involved in regenerating firefly luciferin | |
| Chiang et al. | Purification and properties of porcine gastricsin | |
| JPS61162184A (ja) | 新規な線溶酵素およびその取得法 | |
| BG64875B1 (bg) | Метод за пречистване на тромбиноподобни протеази от змийска отрова | |
| WO2002008249A1 (fr) | Procede de purification de la proteine de liaison a l'ion calcium | |
| Ogawa et al. | Digestion of the fifth component of complement by eosinophil lysosomal enzymes: production of eosinophil specific chemotactic activity | |
| EP0112940B1 (en) | Method of producing a tissue plasminogen activator and composition comprising same | |
| JPH022390A (ja) | 新規なヒト顆粒球マクロファージコロニー刺激因子 | |
| JPH0244510B2 (enrdf_load_stackoverflow) | ||
| Baski et al. | Purification of the restriction endonuclease PalI | |
| Robinson et al. | Partial characterization of in vivo chemotactic activity: comparison to human C5a | |
| Patil et al. | A simple and rapid high recovery protocol for the purification of arginase | |
| Pellegrini et al. | Isolation and characterization of two new low-molecular-weight protein proteinase inhibitors from the granule-rich fraction of equine neutrophilic granulocytes | |
| KR100339153B1 (ko) | 일부봉입체로발현된재조합스트렙토키나제의정제방법 | |
| RU2650755C1 (ru) | Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: EGIS GYOGYSZERGYAR NYRT., HU Free format text: FORMER OWNER(S): EGIS GYOGYSZERGYAR, HU |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |